The Liu Lab

Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapies.

DualADC platform

The Liu lab has developed a dual-payload antibody-drug conjugate (DualADC) platform for conjugating both chemotherapy and immunotherapy drugs to any antibody backbone. The platform utilizes traditional lysine and cysteine residue conjugation sites while employing novel or traditional linkers. The platform enables a drug antibody ratio (DAR) for a subject antibody ranging from 2-14.

Humanized-SSTR2 mAb, ADC, and DualADC

The Liu lab has developed a new humanized antibody that targets SSTR2, somatostatin receptor 2, a powerful target for treating Neuroendocrine Tumors (NETs) and meningiomas. The inventors have developed a stable CHO production cell line for the humanized SSTR2 antibody.

Dr. Liu's lab has xenograft meningioma studies showing traversal of the blood brain barrier and specific tumor targeting with murine-anti-human-SSTR2 mAb. For the Humanized SSTR2-Dual ADC, her lab has preclinical data in NET in vitro studies with NET and meningioma xenograft mouse models studies ongoing.

Additional programs in process:

mAbs: lipolysis simulated lipoprotein receptor (LSR), CD151, CD97, CD146, CD9, CD109, CD166, FGFR4, EpCAM, CD47

Targeted drug delivery: mAb-EV or mAb-LNP

Cancer mitochondrial luminopotogenetics: mitochondria-targeted gene therapies delivered with AAVs or mAB-Exo-AAV